TCGFB, a private biotech founded by healthcare VC The Column Group, is tapping California biotech Surrozen to discover ...

Research collaboration to leverage Surrozen’s antibody research capabilities and expertise to discover a potential first in class treatment for patients with Idiopathic Pulmonary FibrosisSOUTH SAN ...

After pathology and CT review ... Albritton FD, Kingdom TT. Cystic Fibrosis and Nasal Polyposis. MedGenMed 2(1), 2000 [formerly published in Medscape Pulmonary Medicine eJournal 4(1), 2000].

The topline data showed ISM001-055 to have improved the forced vital capacity (FVC) of IPF patients studied 12 weeks after ...

Concurrent pulmonary fibrosis and lung cancer have been linked to poorer outcome ... on imaging or within the postoperative histology was determined. Postoperative outcomes were compared between the ...

A new study by a team of 12 thoracic surgeons at Memorial Sloan Kettering Cancer Center (MSK), published recently in the ...

Substantial enrollment progress in Phase 1b trial of SZN-043 in severe alcohol-associated hepatitis patients with proof-of-concept data expected ...

Interested parties may access the live audio webcast for each conference via the Investors section of the Surrozen website at https://investors.surrozen.com/events-presentations/events-calendar. A ...

"I love offering this innovative, minimally invasive technique for treating Haglund's Syndrome and insertional Achilles pathology," said Dr. Vesely ... ISM001-055 for the Treatment of Idiopathic ...